End Stage Kidney Disease (ESRD) pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook
2020 End Stage Kidney Disease (ESRD) PIPELINE HIGHLIGHTS
End Stage Kidney Disease (ESRD) is one of the widely researched conditions during 2020 with 8 companies actively focusing on realizing pipeline’s potential. Development of End Stage Kidney Disease (ESRD) medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global End Stage Kidney Disease (ESRD) market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for End Stage Kidney Disease (ESRD).
Good progress is anticipated during 2020 and 2021 with End Stage Kidney Disease (ESRD) pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. End Stage Kidney Disease (ESRD) pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
End Stage Kidney Disease (ESRD) DRUG DEVELOPMENT PIPELINE OVERVIEW
The “End Stage Kidney Disease (ESRD) pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This End Stage Kidney Disease (ESRD) pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
The competitive intelligence report on End Stage Kidney Disease (ESRD) presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the End Stage Kidney Disease (ESRD) pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
End Stage Kidney Disease (ESRD) DRUG PROFILES
End Stage Kidney Disease (ESRD) development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
Both small size and large size pharmaceutical companies are investing their resources in End Stage Kidney Disease (ESRD) drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of End Stage Kidney Disease (ESRD). Partnerships and acquisitions are also increasingly observed in the pipeline.
This research report presents an analysis of 8 End Stage Kidney Disease (ESRD) companies including company overview, key snapshot, contact information, and their strategies on accelerating End Stage Kidney Disease (ESRD) pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.
Companies analyzed in the report include- Aronora Inc, BioAegis Therapeutics Inc, Daiichi Sankyo Co Ltd, ITB Med AB, Kiniksa Pharmaceuticals Ltd, Merck & Co Inc, Sanofi, VESSL Therapeutics Ltd
REASONS TO BUY
End Stage Kidney Disease (ESRD) is one of the widely researched conditions during 2020 with 8 companies actively focusing on realizing pipeline’s potential. Development of End Stage Kidney Disease (ESRD) medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global End Stage Kidney Disease (ESRD) market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for End Stage Kidney Disease (ESRD).
Good progress is anticipated during 2020 and 2021 with End Stage Kidney Disease (ESRD) pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. End Stage Kidney Disease (ESRD) pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
End Stage Kidney Disease (ESRD) DRUG DEVELOPMENT PIPELINE OVERVIEW
The “End Stage Kidney Disease (ESRD) pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This End Stage Kidney Disease (ESRD) pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
The competitive intelligence report on End Stage Kidney Disease (ESRD) presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the End Stage Kidney Disease (ESRD) pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
End Stage Kidney Disease (ESRD) DRUG PROFILES
End Stage Kidney Disease (ESRD) development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
- Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
- Phase of development
- Mechanism of Action
- Route of Administration
- Companies involved including originator, licensing companies, developer, investors, and others
- New molecular entity details
- Orphan drug designation and other special status provided by regulators
Both small size and large size pharmaceutical companies are investing their resources in End Stage Kidney Disease (ESRD) drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of End Stage Kidney Disease (ESRD). Partnerships and acquisitions are also increasingly observed in the pipeline.
This research report presents an analysis of 8 End Stage Kidney Disease (ESRD) companies including company overview, key snapshot, contact information, and their strategies on accelerating End Stage Kidney Disease (ESRD) pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.
Companies analyzed in the report include- Aronora Inc, BioAegis Therapeutics Inc, Daiichi Sankyo Co Ltd, ITB Med AB, Kiniksa Pharmaceuticals Ltd, Merck & Co Inc, Sanofi, VESSL Therapeutics Ltd
REASONS TO BUY
- The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
- This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
- Buyers can identify most promising drug candidates for treatment of End Stage Kidney Disease (ESRD)
- It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
- Users can estimate possible delays in the delivery of pipeline or launch of new products
- Stay ahead of competition through understanding their pipeline progression, strategies and outlook
- The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
- Optimize your licensing and technology transfer strategies through identification of prospect partners
1. INTRODUCTION TO END STAGE KIDNEY DISEASE (ESRD)
1.1 End Stage Kidney Disease (ESRD)- Disease overview
1.2 End Stage Kidney Disease (ESRD)- Market Size
1.3 End Stage Kidney Disease (ESRD)- Companies Involved
2. END STAGE KIDNEY DISEASE (ESRD) PIPELINE SNAPSHOT- 2020
2.1 End Stage Kidney Disease (ESRD) Pipeline by Phase
2.2 End Stage Kidney Disease (ESRD) Pipeline by Mechanism of Action
2.3 End Stage Kidney Disease (ESRD) Pipeline by Route of Administration
2.4 End Stage Kidney Disease (ESRD) Pipeline- New Molecular Entities
2.5 End Stage Kidney Disease (ESRD) Pipeline- Orphan Drug Designation/ Special Designation
3. END STAGE KIDNEY DISEASE (ESRD) DRUG PROFILES
3.1 Current Status
3.2 End Stage Kidney Disease (ESRD) Drug Snapshot
3.3 End Stage Kidney Disease (ESRD) Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Aronora Inc End Stage Kidney Disease (ESRD) Pipeline Insights and Clinical Trials
4.2 BioAegis Therapeutics Inc End Stage Kidney Disease (ESRD) Pipeline Insights and Clinical Trials
4.3 Daiichi Sankyo Co Ltd End Stage Kidney Disease (ESRD) Pipeline Insights and Clinical Trials
4.4 ITB Med AB End Stage Kidney Disease (ESRD) Pipeline Insights and Clinical Trials
4.5 Kiniksa Pharmaceuticals Ltd End Stage Kidney Disease (ESRD) Pipeline Insights and Clinical Trials
4.6 Merck & Co Inc End Stage Kidney Disease (ESRD) Pipeline Insights and Clinical Trials
4.7 Sanofi End Stage Kidney Disease (ESRD) Pipeline Insights and Clinical Trials
4.8 VESSL Therapeutics Ltd End Stage Kidney Disease (ESRD) Pipeline Insights and Clinical Trials
5. END STAGE KIDNEY DISEASE (ESRD) MARKET NEWS AND UPDATES
6. APPENDIX
6.1 Sources and Methodology
6.2 Contact Information
1.1 End Stage Kidney Disease (ESRD)- Disease overview
1.2 End Stage Kidney Disease (ESRD)- Market Size
1.3 End Stage Kidney Disease (ESRD)- Companies Involved
2. END STAGE KIDNEY DISEASE (ESRD) PIPELINE SNAPSHOT- 2020
2.1 End Stage Kidney Disease (ESRD) Pipeline by Phase
2.2 End Stage Kidney Disease (ESRD) Pipeline by Mechanism of Action
2.3 End Stage Kidney Disease (ESRD) Pipeline by Route of Administration
2.4 End Stage Kidney Disease (ESRD) Pipeline- New Molecular Entities
2.5 End Stage Kidney Disease (ESRD) Pipeline- Orphan Drug Designation/ Special Designation
3. END STAGE KIDNEY DISEASE (ESRD) DRUG PROFILES
3.1 Current Status
3.2 End Stage Kidney Disease (ESRD) Drug Snapshot
3.3 End Stage Kidney Disease (ESRD) Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Aronora Inc End Stage Kidney Disease (ESRD) Pipeline Insights and Clinical Trials
4.2 BioAegis Therapeutics Inc End Stage Kidney Disease (ESRD) Pipeline Insights and Clinical Trials
4.3 Daiichi Sankyo Co Ltd End Stage Kidney Disease (ESRD) Pipeline Insights and Clinical Trials
4.4 ITB Med AB End Stage Kidney Disease (ESRD) Pipeline Insights and Clinical Trials
4.5 Kiniksa Pharmaceuticals Ltd End Stage Kidney Disease (ESRD) Pipeline Insights and Clinical Trials
4.6 Merck & Co Inc End Stage Kidney Disease (ESRD) Pipeline Insights and Clinical Trials
4.7 Sanofi End Stage Kidney Disease (ESRD) Pipeline Insights and Clinical Trials
4.8 VESSL Therapeutics Ltd End Stage Kidney Disease (ESRD) Pipeline Insights and Clinical Trials
5. END STAGE KIDNEY DISEASE (ESRD) MARKET NEWS AND UPDATES
6. APPENDIX
6.1 Sources and Methodology
6.2 Contact Information
